HFZS
839725
Hangzhou SDIC Microelectronics Inc.
688130
Henan Liliang Diamond
301071
Sf Diamond Co., Ltd.
300179
Jiangsu Zhengdan Chemical Industry
300641
CN Stock MarketDetailed Quotes
600511 China National Medicines Corporation
- 34.69
- +0.04+0.12%
Not Open Dec 23 15:00 CST
26.17BMarket Cap12.09P/E (TTM)
35.14High34.32Low45.50KlotVolume34.60Open34.65Pre Close158.17MTurnover0.82%Turnover Ratio12.20P/E (Static)754.50MShares38.0052wk High1.58P/B19.20BFloat Cap26.3352wk Low38.12Limit Up553.35MShs Float60.06Historical High31.19Limit Down2.37%Amplitude-4.44Historical Low0.85Dividend TTM34.76Avg Price18.87KlotAsk2.46%Div YieldTTM100Lot Size24.69KlotBid
China National Medicines Corporation Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | 3.41%38.97B | 2.85%24.95B | 4.72%11.66B | 6.93%54.19B | 4.71%37.68B | -0.73%24.26B | -4.08%11.14B | 1.65%50.67B | 1.81%35.99B | 4.27%24.43B |
| Refunds of taxes and levies | -41.24%533.69K | 156.75%286.28K | 101.75%153.54K | -90.81%1.05M | -92.05%908.3K | -95.88%111.5K | -83.56%76.1K | 1,439.17%11.42M | 6,284.64%11.42M | --2.71M |
| Cash received relating to other operating activities | 148.52%589.25M | 89.19%383.3M | 27.15%166.86M | 11.85%289.15M | 8.84%237.11M | 8.66%202.61M | 102.95%131.23M | -50.77%258.52M | -57.29%217.85M | -32.69%186.46M |
| Cash inflows from operating activities | 4.32%39.56B | 3.57%25.33B | 4.99%11.83B | 6.93%54.48B | 4.70%37.92B | -0.66%24.46B | -3.49%11.27B | 1.13%50.94B | 1.00%36.22B | 3.85%24.62B |
| Goods services cash paid | 6.74%37.98B | 7.29%24.77B | 10.70%12.77B | 6.42%48.5B | 4.16%35.59B | 0.25%23.09B | -4.44%11.54B | 0.54%45.57B | 2.83%34.16B | 7.63%23.03B |
| Staff behalf paid | 2.19%645.38M | 2.82%451.5M | 2.69%265.61M | 5.34%847.89M | 4.52%631.53M | 5.70%439.13M | 5.24%258.65M | 9.80%804.9M | 11.84%604.21M | 11.69%415.47M |
| All taxes paid | 14.41%1.13B | 23.21%799.14M | -4.46%383.51M | 6.57%1.45B | 0.60%984.69M | -11.68%648.58M | -17.30%401.42M | 4.67%1.36B | -0.94%978.8M | 24.08%734.37M |
| Cash paid relating to other operating activities | 17.10%833.17M | -16.32%375.77M | -39.41%131.93M | 17.81%954.13M | 5.90%711.51M | 10.05%449.03M | 18.99%217.74M | -23.56%809.92M | -17.08%671.85M | -24.65%408.04M |
| Cash outflows from operating activities | 7.06%40.59B | 7.20%26.4B | 9.16%13.55B | 6.59%51.75B | 4.11%37.91B | 0.15%24.62B | -4.41%12.41B | 0.27%48.55B | 2.41%36.42B | 7.36%24.59B |
| Net cash flows from operating activities | -11,267.47%-1.03B | -541.93%-1.07B | -50.28%-1.72B | 13.84%2.73B | 104.67%9.22M | -575.27%-166.06M | 12.58%-1.14B | 22.36%2.4B | -165.89%-197.66M | -95.67%34.94M |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | 200.59%22.92M | 143.40%18.56M | 2,869.04%18.56M | -30.89%7.88M | -33.11%7.63M | -33.11%7.63M | --625.17K | 407.10%11.4M | 407.10%11.4M | 407.10%11.4M |
| Cash received from returns on investments | -45.63%3.2M | -45.86%3.19M | -99.90%5.34K | 347.33%7.77M | 244.98%5.89M | 375.78%5.89M | --5.22M | -39.31%1.74M | -39.75%1.71M | -56.31%1.24M |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | 128.56%347.43K | -10.18%85.64K | 2,084.29%83.44K | -95.43%161.05K | -94.35%152.01K | 867.04%95.35K | -41.41%3.82K | 349.78%3.52M | 310.17%2.69M | -49.41%9.86K |
| Cash received relating to other investing activities | ---- | ---- | ---- | ---- | -99.33%57.76K | -98.82%57.76K | ---- | ---- | -79.48%8.68M | --4.88M |
| Cash inflows from investing activities | 92.91%26.47M | 59.78%21.83M | 219.03%18.65M | -5.07%15.81M | -43.94%13.72M | -22.03%13.66M | -66.15%5.85M | 182.63%16.66M | -49.05%24.48M | 243.69%17.52M |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | 2.86%100.54M | -9.34%60.35M | -9.50%19.6M | 11.83%145.12M | 6.82%97.75M | 56.21%66.57M | 3.35%21.66M | 36.51%129.78M | 46.59%91.51M | 28.48%42.61M |
| Cash paid to acquire investments | --1.38M | --1.38M | --1.38M | ---- | ---- | ---- | ---- | 33.33%24M | -29.04%24M | ---- |
| Net cash paid to acquire subsidiaries and other business units | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -3.92%15.2M | --15.2M | --15.2M |
| Cash paid relating to other investing activities | --66.05M | --66.05M | ---- | ---- | ---- | ---- | ---- | ---- | --161.75K | --161.75K |
| Cash outflows from investing activities | 71.83%167.97M | 91.95%127.77M | -3.15%20.98M | -14.12%145.12M | -25.31%97.75M | 14.82%66.57M | 3.35%21.66M | 31.11%168.98M | 35.97%130.88M | 74.81%57.97M |
| Net cash flows from investing activities | -68.39%-141.5M | -100.26%-105.94M | 85.27%-2.33M | 15.11%-129.31M | 21.02%-84.03M | -30.78%-52.9M | -328.50%-15.82M | -23.85%-152.32M | -120.71%-106.4M | -44.12%-40.45M |
| Financing cash flow | ||||||||||
| Cash from borrowing | 22.69%283.11M | -7.54%154.59M | -90.47%9.53M | -39.45%203.2M | -29.80%230.75M | -26.89%167.2M | 100.00%100M | -57.69%335.61M | -40.46%328.69M | -49.41%228.69M |
| Cash received relating to other financing activities | ---- | ---- | 20.82%328.67M | -19.44%276.47M | -57.83%304.47M | -99.30%1.85M | -8.33%272.03M | 19.13%343.2M | -56.73%721.99M | -27.24%262.89M |
| Cash inflows from financing activities | -47.10%283.11M | -8.55%154.59M | -9.09%338.2M | -29.34%479.67M | -49.06%535.22M | -65.61%169.04M | 7.29%372.03M | -37.22%678.81M | -52.69%1.05B | -39.56%491.58M |
| Borrowing repayment | 6.36%267.26M | -12.53%176.06M | 0.00%100M | -50.97%250M | -44.52%251.27M | -42.95%201.27M | -64.20%100M | -41.03%509.86M | 4.75%452.94M | -16.08%352.78M |
| Dividend interest payment | 4.41%758.67M | 8.13%733.82M | 14.58%62.11M | 12.83%780.14M | 10.95%726.62M | 12.56%678.67M | 39.23%54.21M | -11.42%691.46M | -10.94%654.92M | -2.86%602.97M |
| -Including:Cash payments for dividends or profit to minority shareholders | -24.48%29.61M | 26.39%28.73M | 23.34%28.04M | -11.24%70.56M | -2.02%39.2M | 39.31%22.73M | --22.73M | -44.35%79.5M | -68.87%40.01M | -62.99%16.32M |
| Cash payments relating to other financing activities | 40.23%728.1M | 158.93%391.33M | 6.18%59.5M | -30.21%81.71M | 2.39%519.2M | 177.84%151.13M | -65.58%56.04M | -35.70%117.07M | -59.92%507.07M | 262.72%54.4M |
| Cash outflows from financing activities | 17.16%1.75B | 26.20%1.3B | 5.41%221.62M | -15.67%1.11B | -7.30%1.5B | 2.07%1.03B | -56.30%210.25M | -27.85%1.32B | -33.62%1.61B | -4.35%1.01B |
| Net cash flows from financing activities | -52.92%-1.47B | -33.01%-1.15B | -27.94%116.58M | 1.16%-632.18M | -70.47%-961.87M | -66.23%-862.03M | 220.44%161.78M | 14.26%-639.57M | -165.97%-564.25M | -113.59%-518.56M |
| Net cash flow | ||||||||||
| Net increase in cash and cash equivalents | -154.88%-2.64B | -114.48%-2.32B | -60.80%-1.61B | 22.58%1.97B | -19.39%-1.04B | -106.27%-1.08B | 31.00%-998.45M | 47.29%1.6B | -2,290.49%-868.31M | -197.73%-524.07M |
| Add:Begin period cash and cash equivalents | 22.25%10.8B | 22.25%10.8B | 22.25%10.8B | 22.17%8.83B | 22.17%8.83B | 22.17%8.83B | 22.29%8.83B | 17.72%7.23B | 17.72%7.23B | 17.72%7.23B |
| End period cash equivalent | 4.61%8.16B | 9.39%8.48B | 17.33%9.19B | 22.25%10.8B | 22.56%7.8B | 15.60%7.75B | 35.65%7.83B | 22.17%8.83B | 2.92%6.36B | 0.42%6.71B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
